

Price transparency in the prescription drug market is a necessity for New Mexico to shed light on the excessive profits and corporate practices that make medications unaffordable for those who need them. According to a 2020 poll*, 44% of New Mexicans have skipped taking or not filled a prescription due to costs. 9 in 10 New Mexicans are either very or somewhat concerned about the cost of drugs, with 62% very concerned.

Policy makers and the public need access to the full picture of the drivers of high drug costs throughout the supply chain, both to hold these entities accountable for price hikes and profiteering, and to inform effective policy to lower costs for consumers.

The NM Consumers for Affordable Prescriptions Coalition is anchored at Health Action NM, and is comprised of nearly 30 NM-based organizations representing patients, patient advocates, providers and other constituencies affected by the high cost of drugs. We are eager to mobilize our coalition, and the many affected New Mexicans who have shared their stories with us about financial hardships and negative health impacts that they are experiencing due to high drug costs, in support of a prescription drug price transparency bill.

Under this legislation, entities in the supply chain will be required to open their books and report to the Superintendent of Insurance on profits, prices increases, negotiated rebates, and more.

• Manufacturers will be required to report when a drug meets a price threshold for a month's supply (\$400 a month), or when the cost of a drug is increased by a high percentage (16% over two years), as well as details like patient financial assistance, profits, etc.

All reporting entities will be subject to a financial penalty for failure to comply.

- Wholesalers/distributors will report on the drugs that are most frequently ordered, are most costly, and have contributed most to increases in total spending.
- PBMs will be required to disclose negotiated discounts/rebates provided to consumers
- **Insurance carriers** will report on the drugs that are most frequently prescribed, are most costly, and have contributed most to plan spending and patient cost.

OSI will compile this information and report to the legislature and the public on price trends and other insights. Policy makers will no longer have to rely on industry lobbyists for information on the causes of and solutions for high prescription drug costs.

Please join us in calling on the Governor and NM legislature to support drug price transparency in the 2024 legislative session. Prescriptions don't work if people can't afford them.

NM Consumers for Affordable Prescriptions & Health Action NM

Gabriella Rivera | gabriella @healthactionnm.org